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Background
Replication-defective SIV elicited protective immunity in
animals. In this first-in-human therapeutic vaccination
study, a replication-defective HIV-1 vaccine was tested
in HIV-1 infected subjects under antiretroviral therapy.
Methods
A010 is an ongoing randomized, placebo-controlled
dose-escalation clinical trial to evaluate the safety and the
immunogenicity of two doses of a replication defective
HIV-1 vaccine (HIVAX™) in subjects receiving stable
highly active antiretroviral therapy (HAART) who have
an HIV-1 RNA <50 copies/ml and CD4 cell count >500
cells/mm3. Following the randomized placebo-controlled
vaccination phase subjects who received active vaccine
and who meet eligibility will undergo a 12-week analyti-
cal antiretroviral treatment interruption.
Results
HIVAX™ is well tolerated in HIV infected subjects. Only
mild injection site reaction occurred with transient dura-
tion. No medical treatment is necessary. High level of cell-
mediated immune responses measured by ELISPOT assay
was noticed after vaccination.
Conclusion
The replication defective HIV vaccine appears no severe
adverse effect in HIV-1 infected subjects. High level of
cell-mediated immune response was elicited in the vacci-
nees. HIVAX™ is worth for further evaluation of protec-
tive efficacy.
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